Hemab Therapeutics Holdings, Inc. SEC filings COAG
Hemab Therapeutics Holdings, Inc. has 50 filings in SEC EDGAR's recent list, going back to Feb 27, 2026. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 24, 2026 (officer or director change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 4 | Insider transaction | Sep 25, 2026 | Sep 24, 2026 |
| 3 | Initial insider ownership | Sep 25, 2026 | Sep 24, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 24, 2026 | Sep 24, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | Aug 14, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Aug 14, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Aug 12, 2026 | — |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | Aug 7, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Aug 6, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Aug 5, 2026 | — |
| 4 | Insider transaction | Jun 17, 2026 | Jun 15, 2026 |
| 4 | Insider transaction | May 21, 2026 | May 19, 2026 |
| 10-Q | Quarterly report | May 21, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 21, 2026 | May 21, 2026 |
| 4 | Insider transaction | May 14, 2026 | May 12, 2026 |
| 3 | Initial insider ownership | May 14, 2026 | May 4, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | May 11, 2026 | — |
| 4 | Insider transaction | May 11, 2026 | May 7, 2026 |
| SCHEDULE 13D | Ownership over 5% (active) | May 11, 2026 | — |
| 8-K |
Current report
Officer or director change
|
May 11, 2026 | May 8, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | May 8, 2026 | — |
| 4 | Insider transaction | May 6, 2026 | May 4, 2026 |
| 4 | Insider transaction | May 6, 2026 | May 4, 2026 |
| 4 | Insider transaction | May 4, 2026 | Jan 29, 2026 |
| 4 | Insider transaction | May 4, 2026 | Jan 29, 2026 |
| 4 | Insider transaction | May 4, 2026 | Jan 29, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Other events
|
May 4, 2026 | May 4, 2026 |
| S-8 | Employee stock plan registration | May 4, 2026 | — |
| 424B4 | Prospectus | May 1, 2026 | — |
| EFFECT | Filing | Apr 30, 2026 | — |
| 3 | Initial insider ownership | Apr 30, 2026 | Apr 30, 2026 |
| 3 | Initial insider ownership | Apr 30, 2026 | Apr 30, 2026 |
| 3 | Initial insider ownership | Apr 30, 2026 | Apr 30, 2026 |
| 3 | Initial insider ownership | Apr 30, 2026 | Apr 30, 2026 |
| 3 | Initial insider ownership | Apr 30, 2026 | Apr 30, 2026 |
| 3 | Initial insider ownership | Apr 30, 2026 | Apr 30, 2026 |
| 3 | Initial insider ownership | Apr 30, 2026 | Apr 30, 2026 |
| 3 | Initial insider ownership | Apr 30, 2026 | Apr 30, 2026 |
| 3 | Initial insider ownership | Apr 30, 2026 | Apr 30, 2026 |
| 3 | Initial insider ownership | Apr 30, 2026 | Apr 30, 2026 |
| S-1MEF | Filing | Apr 30, 2026 | — |
| CERT | Filing | Apr 30, 2026 | — |
| S-1/A | Amended registration statement | Apr 30, 2026 | — |
| S-1/A | Amended registration statement | Apr 28, 2026 | — |
| 8-A12B | Filing | Apr 27, 2026 | — |
| S-1/A | Amended registration statement | Apr 27, 2026 | — |
| S-1 | Registration statement | Apr 10, 2026 | — |
| DRS/A | Filing | Apr 2, 2026 | — |
| DRS | Filing | Feb 27, 2026 | — |
Showing 50 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- COAG (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 2114044
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.